Am I sure about what?
Sales are not declining. IMS and Symphony both have been under reported since the very start so we won't know the real numbers until the quarterly report. Flat week over week or slightly down on their numbers does not really tell the real story but you know this already.
I am sure they will be up significantly quarter over quarter and they will show a continued growth in scripts, doctors scripting and much better results then the studies indicated. We have now crossed over the 1 year on the market mark with no major events reported from Belviq users and we have had 10's of thousands of folks on it. That will give many doctors the confidence to allow their patients to try Belviq.
Insurance coverage is increasing as well. While the progress has been painfully show we have still had regular progress on all fronts.
Eisai is doing. Getting to hear the I am cheap speech and don't like to spend money. I just don't get him selling on the eve of Eisais big re launch of Belviq. Today is the 7th and the Eisai has started their sales meetings and the motivational break outs and classes. They are going to be launching new initiatives and getting their sales staff pumped to take us to the next level.
Selling half his position makes no sense what so ever to me. Even if he is being forced out or retiring, why would he sell half his stock after pointing out several times he has not been selling any of his shares. Even if he leaves he still believes in Belviq and the market potential for the drug he spent 10 years developing.
There have been several observed adverse side effects from taking Belviq.
Added expense of new clothes purchases.
Added expenses of vacations and trips now that you look good and feel good.
Reduced expenses on your current medication.
Reduced expenses on food and going out.
You will have an increase in birth control expenses now that you look and feel good.
You get the picture...
Have a great day.
Q over Q and Year over Year is the measure Wall Street uses, no one uses week over week for measuring a companies success. We will close this quarter out with a very nice sustainable growth of scripts and revenue completing our first year on the market. Ignore the noise and watch the real data points that matter. IMS under reports by 40% and Symphony is about 20% when compared to the numbers both Eisai and Arena are releasing.
If you are looking to get rich overnight in this stock that is not going to happen. This is going to be a few more years out...
to 42 million shares. Long term shorts still covering their shorts, a great signal in my book.
Look at ZFGN, the new Bio Tech IPO trying to come out with an obesity drug. They are running the thing way up giving it all kinds of attention. Heaven forbid they actually pay attention to the drug that has actually been approved and has multiple indications and great success stories all ready. Read about about the company and how big the obesity market is and how successful they will be if they can get a drug approved... SERIOUSLY, you can't make this stuff up.
The Fiscal Times
By Eric Pianin, Brianna Ehley 5 hours ago
Until now, Americans have been losing the battle of the bulge.
More than a third of all adults and 17 percent of young people are obese, according to the experts, and many of them have been consigned to troubled lives with obesity-related health problems such as type 2 diabetes, coronary heart disease and stroke, hypertension, arthritis and even cancer. Without major government and private intervention and a sea change in many Americans’ unhealthy eating habits, the adult obesity rate could reach 50 percent by 2030, according to one study.
The cost to society in terms of damaged lives, soaring health care costs and diminished economic growth and productivity is staggering.
A new analysis prepared for The Fiscal Times by Scott Kahan, director of the National Center for Weight & Wellness at George Washington University, pegs the total cost of obesity – including direct medical and non-medical services, decreased worker productivity, disability and premature death – at $305.1 billion annually.
Those direct medical costs -- include counseling, outpatient and hospital visits, a range of bariatric surgical procedures, new treatment, nursing home care, rehabilitation and hospice – account for $190 billion of the annual costs, according to Kahan. The non-medical costs, including health education and behavioral change, add $50 billion to the annual tab. Finally, absenteeism and sub-par productivity in the workplace costs an additional $65.1 billion a year.
Kahan’s study, which he based on a wealth of research dating back to 1998, eclipses previous estimates of obesity’s societal and economic costs. The total would be much higher – by at least an additional $300 billion a year – if “intangible costs” associated with pain and suffering from obesity and obesity-associated conditions were added – but they are difficult to monetize. Still, those additional costs would push the grand total to $605 billion a year.
The Rat Tumors are the EU's only issue that has been made public... With the FDA, Arena had to come up with a study that they would sign off on. We may need to do the same thing with EU...
Its a dog and pony show, it will be the same as always. Talking about Belviq, Eisais marketing and their pipeline. Its not BS it is all they really have to talk about, they are working to bring more drugs to the market and that takes years...
Dr. Oz scolded at hearing on weight loss scams, this will go a long way... He is looking like a snake oil salesmen these days.
I was just stating that after such great script numbers I was shocked to see we could not go up one day after the great news. It is getting a little old these days.
Scripts were up 23.2% and 23.8% and the stock could not hold gains. Everyone thought once we caught Qsymia things would change, once we cross 10,000 things would change, now we get a hug script number coming off of a 4 day week and are now higher then Qsyima in total scripts and actual scripts and the stock price still remains manipulated and under pressure. Belviq has been outperforming the market and its competitors since the trend change back in January and we still are not selling based on potential.
Just amazing when you think about all the positives and the good news that has come out of Arena Pharma and Eisai for the last year. We still can't get over the first PDUFA pricing levels...
they hammered it down for the day. Go figure. Oh well, I still believe short interest is still dropping.
really wants to sell their shares at 6.50 since that is as high as this run will ever go... NOT !!!! Shorting at the ask and buying on the bid, classic cover strategy.